Naloxazone: Difference between revisions
Jump to navigation
Jump to search
m Protected "Naloxazone": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 21: | Line 21: | ||
{{CMG}} | {{CMG}} | ||
__NOTOC__ | __NOTOC__ | ||
==Overview== | ==Overview== | ||
| Line 28: | Line 28: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{opioids}} | {{opioids}} | ||
Latest revision as of 20:01, 4 September 2012
Template:Chembox new Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Naloxazone is an irreversible μ opioid receptor antagonist which is selective for the μ1 receptor subtype.[1]
References
- ↑ Pasternak GW, Childers SR, Snyder SH. "Opiate analgesia: evidence for mediation by a subpopulation of opiate receptors." Science. 1980 May 2; 208(4443):514-6. PMID 6245448. doi:10.1126/science.6245448